Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.6 CHF | -1.34% | +2.27% | +15.01% |
Jun. 20 | Basilea Pharmaceutica to Sell Brain Cancer Drug Candidate to US-based Nonprofit | MT |
Jun. 20 | Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.01% | 556M | |
+23.50% | 47.07B | |
+47.98% | 42.06B | |
-5.16% | 39.98B | |
+36.37% | 33.02B | |
-7.79% | 27.9B | |
+18.06% | 27.63B | |
+47.29% | 14.37B | |
+41.91% | 13.45B | |
-1.02% | 12.03B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica to Receive First Milestone Payment for Cresemba from Latin America